GSA Capital Partners LLP Has $1.50 Million Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

GSA Capital Partners LLP grew its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 66.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 93,658 shares of the company’s stock after buying an additional 37,275 shares during the quarter. GSA Capital Partners LLP owned 0.08% of Centessa Pharmaceuticals worth $1,498,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its position in Centessa Pharmaceuticals by 16.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after purchasing an additional 418,615 shares in the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Centessa Pharmaceuticals during the 2nd quarter worth $4,064,000. Driehaus Capital Management LLC lifted its position in shares of Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after buying an additional 987,997 shares during the last quarter. First Light Asset Management LLC lifted its position in shares of Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Finally, Farallon Capital Management LLC boosted its stake in Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after buying an additional 1,625,000 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on CNTA. Jefferies Financial Group increased their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. BMO Capital Markets increased their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. B. Riley started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target for the company. Finally, Guggenheim raised their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $25.17.

Centessa Pharmaceuticals Trading Up 6.4 %

Shares of NASDAQ CNTA opened at $18.08 on Thursday. The firm has a 50 day moving average price of $15.81 and a two-hundred day moving average price of $12.03. The stock has a market cap of $2.05 billion, a P/E ratio of -11.82 and a beta of 1.47. Centessa Pharmaceuticals plc has a 52-week low of $5.58 and a 52-week high of $18.74. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, equities analysts forecast that Centessa Pharmaceuticals plc will post -1.68 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 4,169 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at $10,197,941.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Saurabh Saha sold 4,169 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the transaction, the chief executive officer now owns 827,755 shares in the company, valued at approximately $10,197,941.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 25,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the sale, the insider now owns 223,369 shares of the company’s stock, valued at approximately $3,350,535. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 325,031 shares of company stock worth $5,213,043 over the last ninety days. 11.59% of the stock is owned by insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.